Centre Hospitalier Universitaire de Nice

DUBLIN--( BUSINESS WIRE )--The "Surgical Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive information about the Surgical Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Report Scope Extensive coverage of the Surgical Devices under development The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities The report reviews the major players involved in the development of Surgical Devices and list all their pipeline projects The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage The report provides key clinical trial data of ongoing trials specific to pipeline products Recent developments in the segment/industry The report enables you to: Formulate significant competitor information, analysis, and insights to improve R&D strategies Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage Identify and understand important and diverse types of Surgical Devices under development Develop market-entry and market expansion strategies Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline In-depth analysis of the product's current stage of development, territory and estimated launch date Key Topics Covered 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Surgical Devices Overview 3 Products under Development 3.1 Surgical Devices - Pipeline Products by Stage of Development 3.2 Surgical Devices - Pipeline Products by Segment 3.3 Surgical Devices - Pipeline Products by Territory 3.4 Surgical Devices - Pipeline Products by Regulatory Path 3.5 Surgical Devices - Pipeline Products by Estimated Approval Date 3.6 Surgical Devices - Ongoing Clinical Trials 4 Surgical Devices - Pipeline Products under Development by Companies 4.1 Surgical Devices Companies - Pipeline Products by Stage of Development 4.2 Surgical Devices - Pipeline Products by Stage of Development 5 Surgical Devices Companies and Product Overview 6 Surgical Devices - Recent Developments 7 Appendix 7.1 Methodology List of Tables Surgical Devices - Pipeline Products by Stage of Development Surgical Devices - Pipeline Products by Segment Surgical Devices - Pipeline Products by Territory Surgical Devices - Pipeline Products by Regulatory Path Surgical Devices - Pipeline Products by Estimated Approval Date Surgical Devices - Ongoing Clinical Trials Surgical Devices Companies - Pipeline Products by Stage of Development Surgical Devices - Pipeline Products by Stage of Development Glossary List of Figures Surgical Devices - Pipeline Products by Stage of Development Surgical Devices - Pipeline Products by Segment Surgical Devices - Pipeline Products by Territory Surgical Devices - Pipeline Products by Regulatory Path Surgical Devices - Pipeline Products by Estimated Approval Date Surgical Devices - Ongoing Clinical Trials Companies Mentioned 6S Medical LLC Abbott Operations Uruguay Srl Acoustic MedSystems Inc Aesculap Inc Anastom Surgical Anchora Medical Ltd Apercure Surgical Ltd Apollo Endosurgery Inc Applied Medical Resources Corporation Apyx Medical Corp Archon Medical Technologies LLC Augusta University Baxter International Inc BioTex Inc BriteSeed BTG International Inc Carnegie Mellon University Centre Hospitalier Universitaire de Nice Charite University Hospital of Berlin Chengdu Yurui Innovation Technology Co Ltd Colospan Ltd Control Medical Technology LLC Core Essence Orthopaedics, LLC Corporis Medical Covidien Ltd CR Bard Inc Creative Balloons GmbH Cryofocus Medtech Shanghai Co Ltd CT Resources Inc Cutera Inc Cypris Medical, Inc. Dartmouth College Deep Blue Medical Advances Inc Drexel University Emblation Ltd Embricon Ltd (Inactive) Endo Tools Therapeutics SA EndoEvolution, LLC Ethicon Endo-Surgery Inc ExpandoHeat LLC Fixit Medical Ltd Fogless International AB G.I. Windows Inc Galil Medical Ltd Garantis Genicon Inc GI Windows Medical Corp Grand Valley State University H. Lee Moffitt Cancer Center & Research Institute Inc Hangzhou Kangsheng Medical Equipment Co Ltd Hannover Medical School Harvard University Hospital for Special Surgery IceCure Medical Ltd Imperial College London Indian Institute of Technology Delhi Innovex Medical Co Ltd Integra LifeSciences Holdings Corp Intuitive Surgical Inc IonMed Ltd. Jinan Micro Intelligent Technology Co Ltd Johns Hopkins University Keren Medical Ltd. LeMaitre Vascular Inc Livsmed Inc LuSeed Vascular Lymphatica Medtech SA MagniFeel Surgical Instruments Mayo Clinic Mecmaan Healthcare Ltd Medical University of South Carolina MediShield B.V. Medtronic Plc Mel Frontier Co Ltd Meta Biomed Co Ltd Michigan State University Naval Medical Research Center Next Science Ltd NorthShore University Health System NOvate Medical Technologies, LLC NoviRad Inc NovoGI LTD Novolock Ltd Novuson Surgical, Inc. Ohio State University Oklahoma State University Olympus America Inc OV World Co Ltd Pacira BioSciences Inc Parker Hannifin Corp Pavmed Inc PetVivo Holdings Inc Physcient, Inc. Polytechnic University of Catalonia Pro-Dex Inc Queen Mary University of London Ra Medical Systems Inc Ramona Optics Inc Ratner BioMedical Inc Resultados y Calidad del Sistema Sanitario Publico de Andalucia Rice University Saint Louis University Samyang Biopharmaceuticals Corp Sanovas Inc Shanghai MicroPort Medical Group Co Ltd Shanghai Shengzhe Medical Technology Co Ltd Shanghai Yichao Medical Equipment Co Ltd Silmag SA simedeq Simon Fraser University StatLink Surgical STRATA Skin Sciences Inc Stryker Corp SurgyAid, LLC Sutura Inc Teleflex Inc Tepha Inc The Feinstein Institute for Medical Research TransMed7 LLC Trinity College Dublin University of Auckland University of California University of California Davis University of California Los Angeles University of California San Diego University of Central Florida University of Chicago University of Maryland University of Maryland Baltimore University of Minnesota University of Missouri University of North Carolina University of South Florida University of Strasbourg University of Texas at Austin University of Texas Medical Branch at Galveston University of Toledo University of Utah University of Virginia US Medical Innovations LLC USGI Medical Inc Vanderbilt University Vascular Insights LLC VB Devices Vessi Medical Ltd Viveve Medical Inc Viveve, Inc. Wake Forest Baptist Medical Center Weill Cornell Medical College West Virginia University X-Biomedical Inc For more information about this report visit https://www.researchandmarkets.com/r/ekyrrp Source: GlobalData

Global biopharmaceutical company, Almirall, and Inserm Transfert – the private subsidiary of the French National Institute of Health and Medical Research (Inserm) – have announced plans to collaborate under a new licencing agreement. The companies will work together to advance treatment options for people living with vitiligo, develop a more in-depth understanding of dermatological diseases and allow further access to new technologies and the discovery of new therapeutic approaches. As a chronic skin condition that affects 0.5 to 2% of the worldwide population, vitiligo is associated with a loss of pigmentation and the visibility of patients’ lesions is often seen as disfiguring and a burden. As a result, patients can experience a high level of psychological impact, alongside treatment needs. Vitiligo remains a neglected market with a high unmet medical need for treatments, particularly for patients’ hands. The collaboration agreement, signed by Inserm Transfert on behalf of Inserm, Centre Hospitalier Universitaire of Nice and University of Nice Côte d’Azur, aims to identify and develop a novel class of medicines that modulate a key target involved in skin repigmentation, the Wnt pathway. According to the terms of the agreement, Almirall has received global rights to Inserm’s background patents on the use of Wnt agonists in the treatment of vitiligo. Inserm Transfert’s involvement in this deal is part of Almirall’s SHINE initiative, which was launched to drive innovation in dermatology by putting a spotlight on collaborations with centres of excellence. Examples of this have included the partnerships with the University of Dundee and the University of Michigan. Professor Thierry Passeron and his team at the Mediterranean Centre for Molecular Medicine will work with the partnership. Professor Passeron has spearheaded research in vitiligo and will combine this with Almirall's background in drug discovery to identify and develop new topical compounds for the treatment of vitiligo. Karl Ziegelbauer, chief scientific officer at Almirall, said: “Vitiligo can have a huge impact on patients' quality of life. We are pleased to announce this new collaboration with a centre of excellence such as Inserm to develop innovative treatments for this skin condition. This milestone once again demonstrates Almirall's commitment to improving the lives of patients in an underserved disease where there are still significant unmet needs.”